Prague

• A Phase 3, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil and Contezolid Compared … Recruiting
  2022-500257-16-00 5 2023-03-17 Diabetic Foot Infections
• This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi … Recruiting
  2023-505277-32-00 5 2023-01-26 Diffuse Large B-Cell Lymphoma (DLBCL)
• Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA). Recruiting
  2023-507031-38-00 5 2023-01-09 Severe viral lung infections
• A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with NMDAR or LGI1 mediated autoimm … Recruiting
  2023-504226-18-00 5 2022-11-30 NMDAR or LGI1 mediated autoimmune Encephalitis
• Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica … Recruiting
  2023-506548-18-00 10 2022-11-10 Dermatitis atopic
• Evaluation of Niraparib alone compared to the combination of Niraparib and Bevacizumab in patients receiving chemotherapy for newly diagnose … Recruiting
  2024-516066-11-00 5 2022-08-31 Patients with newly diagnosed, histologically confirmed, primary advan
• Phase 3 Trial of TAK-330 for Reversal of Direct Oral Factor Xa Inhibitor-induced Anticoagulation Recruiting
  2022-503012-16-00 5 2022-07-20 Patients on treatment with Factor Xa Inhibitor needing for an urgent i
• A study to evaluate the effect of venglustat tablets on left ventricular mass index in male and female adult participants with Fabry disease Recruiting
  2023-509715-91-00 5 2022-05-06 Fabry’s disease
• A Long-term Follow-up Study of Sotatercept for PAH Treatment Recruiting
  2023-509138-21-00 5 2021-08-26 Pulmonary Arterial Hypertension (PAH)
• An unblinded, multi-center study evaluating long-term treatment with Zanubrutinib (BGB-3111) regimens in patients with blood cancer in the l … Recruiting
  2024-511267-28-00 5 2021-02-17 B-cell malignancies
• Ph 3a, linerixibat, Long term safety and tolerability study in pts with PBC Recruiting
  2023-503465-33-00 5 2020-07-03 Cholestasis
• Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight and Diabetes Recruiting
  2025-523510-87-00 5 2026-06-25 Obesity
• Bioequivalence of Tramadol retard 200 mg Prolonged-Release Tablets in Healthy Subjects Under Fed Conditions Recruiting
  2026-525780-41-00 2 2026-06-22 Not applicable (submitted trial is a bioavailability trial in healthy
• Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes Recruiting
  2025-523486-17-00 5 2026-06-16 Obesity
• A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial Recruiting
  2025-524078-40-00 5 2026-06-10 Chronic Spontaneous Urticaria
• A clinical trial to learn more about the effects of FWY003 in people with geographic atrophy associated with age-related macular degeneratio … Recruiting
  2025-523704-77-00 4 2026-06-04 Geographic atrophy secondary to age-related macular degeneration
• A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizu … Recruiting
  2025-521587-35-00 5 2026-06-03 Metastatic colorectal cancer
• A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or … Recruiting
  2025-523461-17-01 5 2026-06-01 LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
• Identification of mitochondrial biomarkers reflecting omaveloxolone treatment (in FA patients) Recruiting
  2025-523881-26-00 6 2026-05-27 Friedreich's ataxia
• Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting
  2023-503766-24-00 11 2026-05-26 Moderate to Severe Plaque Psoriasis
• A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight and type 2 diabetes Recruiting
  2025-523106-32-00 5 2026-05-25 Obesity or Overweight and Type 2 Diabetes
• A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK-6482-034) Recruiting
  2024-516993-31-00 5 2026-05-11 Renal Cell Carcinoma
• A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin ( ENLIGHTEN-6 ) Recruiting
  2025-523659-73-00 5 2026-05-11 Obesity
• A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight without type 2 diabetes. Recruiting
  2025-523104-71-00 5 2026-05-08 Obesity or Overweight Without Type 2 Diabetes

Showing 145–168 of 850 trials